NK:IO, a leader in natural killer (NK) cell biology applied to the development of potent, off-the-shelf cell therapies targeting solid tumors, has raised £1.2m.
Twist Bioscience, a biotech company manufacturing synthetic DNA, and Cancer Research Horizons, the innovation engine at the core of Cancer Research UK, have announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma...
Launching in April last year, Cancer Research Horizons (CRH) describes itself as the “meeting point” between academia and industry, attempting to prevent drug discoveries from entering the ‘valley of death’ and stalling in their progress.
